Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

orphelia pharma sas - clofarabine - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - trattament ta ' akuta lymphoblastic lewċemja (kollha) fil-pazjenti pedjatriċi li jkunu relapsed jew huma refrattorju wara li jirċievu mill-inqas żewġ reġimi minn qabel u fejn hemm l-ebda oħra trattament għażla antiċipat li jirriżultaw fi tweġiba dejjiema. is-sigurtà u l-effikaċja ġew ivvalutati fi studji ta 'pazjenti ta' ≤ 21 sena fid-dijanjożi inizjali.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - cannabidiol - lennox gastaut syndrome; epilepsies, myoclonic - anti-epilettiċi, - epidyolex huwa indikat għall-użu bħala terapija aġġuntiva ta 'aċċessjonijiet assoċjati mas-sindrome lennox gastaut (lgs) jew sindromu ta'dravet (ds), flimkien ma' clobazam, għall-pazjenti 2 snin ta ' età u anzjani.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - fibrożi ċistika - prodotti oħra tas-sistema respiratorja - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosoppressanti - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - sera immuni u immunoglobulini, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumur stromali gastrointestinali - aġenti antineoplastiċi - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - majloma multipla - aġenti antineoplastiċi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegaly - ormoni u analogi pitwitarji u ipotalamiċi - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

gmp-orphan sa - trientene tetraidroklorur - deġenerazzjoni epatoġenika - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - cuprior huwa indikat għall-kura ta 'wilson tal-marda fl-adulti, l-adoloxxenti u t-tfal ta' ≥ 5 snin li ma jittollerawx d-penicillamine-terapija.